Corporate Innovation vs Start-up Innovation: Same Destination, Different Journey

Having worked in and with both small and large organizations to bring innovative products to patients, it is interesting to reflect on what it takes to be successful in each environment. Understanding these differences is important for people considering a move between organizations, for start-ups looking to hire talent from larger corporations, and for teams that need to collaborate effectively across organizational boundaries.

In this article, we briefly discuss the differences in processes and ways of working between large and small organizations. In future articles, we will dive deeper into specific functions such as engineering, regulatory affairs, sales, marketing, and general management, highlighting key considerations for people moving between organizations and for companies hiring talent from a different organizational background.

Corporate Innovation: Best-in-Class on Paper, Silo Optimization in Practice

Large, established organizations typically have a long history of doing things in a structured way. Companies that have completed dozens of product updates, clinical studies, regulatory submissions, and commercial launches have had many opportunities to refine their processes. In theory, this experience should enable them to learn from past mistakes and continuously improve execution.

As a result, these organizations often possess not only substantial institutional knowledge but also detailed quality management system (QMS) procedures, templates, and standardized ways of working. Their size allows entire departments to own specific processes, each with its own management structure, KPIs, and performance targets.

On paper, this should lead to best-in-class execution. In practice, however, it can result in local optimization within organizational silos. This works well when the company is focused on delivering existing products to existing customers. New product variants or incremental improvements can be rolled out at scale, driving rapid market adoption. The performance of this core business is critical because it pays today’s salaries and drives the quarterly financial results reported throughout the organization. Consequently, most incentives are aligned toward maintaining and optimizing existing revenue streams.

Developing truly innovative products is fundamentally different. Unlike incremental improvements, breakthrough innovations often require changes across multiple functions and processes. Such innovative products may demand different business models, clinical evidence strategies, regulatory approaches, manufacturing processes, and sales methods. Implementing these changes can create significant friction within organizations that are optimized for consistency and predictability.

A truly novel product may require new QMS procedures, different types of clinical evidence, alternative reimbursement models, or entirely new approaches to commercialization. Because each of these activities is controlled by separate departments using established tools and processes, change becomes difficult. Even when an innovation is strategically important and has significant long-term potential, work on it can be viewed as a distraction from the activities that support this year’s targets.

Innovation budgets often only rise and fall with the performance of the core business. Since the actual progress of a development program typically has little immediate impact on continued funding, urgency can be limited. Even when progress falls short of expectations, projects may continue as long as their perceived future value remains higher than competing internal opportunities.

To address these challenges, many large companies establish internal ventures or incubators that operate at a greater distance from day-to-day operations. In principle, this creates a more integrated environment where regulatory, development, and commercial activities can be aligned around a single objective. It appears to offer the best of both worlds.

In reality, however, these ventures often remain constrained by the parent organization’s structures. Budgets are frequently allocated through annual operating plans rather than milestone-based funding. Staff are commonly recruited from within the organization and naturally bring established ways of working with them. Because they typically do not participate directly in the venture’s upside, they retain the job security and incentives associated with the core business.

Process innovation is also often limited. For example, the venture usually remains within the scope of the parent company’s QMS certification. This restricts the flexibility that can be introduced without creating audit findings or compliance concerns. As a result, central quality and regulatory teams often remain heavily involved, limiting the venture’s ability to adopt alternative approaches that may be more appropriate for an early-stage innovation.

Further down the line, when the product is ready for commercial launch, companies hope to leverage their existing sales organization and customer base. However, sales incentives remain largely tied to the performance of the core portfolio. Sales teams are often happy to showcase innovative technologies as part of broader customer discussions, but they have limited incentive to prioritize closing deals for a product that contributes relatively little to their targets.

The last thing a sales team wants is to jeopardize established customer relationships. As a result, organizations frequently spend additional time optimizing a product before launch in an effort to minimize early problems. Yet the most valuable feedback often only emerges once real customers begin using the product in day to day clinical practice. The scale of the organization and the complexity of its processes can make it difficult to respond quickly to this feedback and implement meaningful improvements.

In the end the inertia of a big corporate can often help to support the required continued investment to slowly build up the required evidence and experience to reach market success. The existing business is able to fund the required investments in a way that most scale ups are unable to sustain, leading to a measure of adoption in the end.

Innovation in Start-ups and Scale-ups: Controlled Chaos in a Pressure Cooker

As discussed previously, the milestone-based funding model of most start-ups has a profound impact on how innovation and product development are managed. Since future funding is uncertain, companies must continuously reduce risk and increase the value of their technology. This requires careful consideration of the milestones that drive investment decisions and strategic progress.

At the same time, one of the greatest challenges is building an organization capable of executing effectively. Success depends on assembling the right team and collectively defining ways of working that fit the stage of the business. Unlike large corporations, start-ups have no shared history to fall back on. Almost every activity is being performed for the first time: the first prototype tests, first clinical studies, first regulatory submissions, and hopefully the first commercial sales. This creates an environment that can feel chaotic and inefficient. Successfully navigating this uncertainty requires the entire team to understand the company’s mission, current stage of development, and the priorities that matter most.

Providing this clarity is one of the management team’s most important responsibilities. Together with the broader team, leadership must continually determine what creates value today and what can be deferred until later (see previous post). Teams with this clarity are often able to move remarkably quickly, accelerating both innovation and market access.

Supporting this pace of innovation in a compliant manner requires a QMS that is fit for purpose. Rather than implementing unnecessary complexity too early, the quality system should be aligned with the maturity of the product and organization. Achieving this requires quality and regulatory professionals who can balance compliance requirements with the practical needs of a growing business.

Ultimately, the greatest challenge in bringing innovative medical devices to patients is achieving market acceptance. Strong clinical outcomes or patient benefits alone are rarely sufficient to create meaningful commercial traction. Someone must ultimately pay for the innovation, making it essential to understand how economic value will be captured within the healthcare system.

This often requires creative and unconventional thinking from the business development team. Identifying the ideal early customers, those most likely to benefit and willing to pay, is critical. Success frequently depends on generating the right economic and clinical evidence, finding the right commercial partners, and targeting markets where adoption barriers are lower (see previous article). Excelling in this environment requires a very different skill set from launching the next product variant within an established customer base. Success depends not only on execution but also on creativity, adaptability, and the ability to make decisions despite uncertainty.

In the end start-ups are often able to quickly bring an innovation to initial market access. However, being able to sustain the always longer than expected road to eventual market acceptance and success can be much more difficult. Surviving this 2nd valley of deathis not easy and requires careful execution and some luck.

Conclusions

Large and small medtech organizations bring innovations to market in fundamentally different ways. Neither approach is inherently better or worse. Large organizations benefit from experience, resources, and the ability to scale rapidly once a product is ready for launch. Start-ups and scale-ups compensate for more limited resources through agility, flexibility, and a willingness to adapt quickly based on customer feedback.

Understanding these differences is particularly important when small companies collaborate with large corporations, whether through joint development programs, strategic partnerships, or M&A activities. Awareness of the differing incentives, decision-making processes, and operating models helps establish realistic expectations and enables both parties to navigate inevitable challenges more effectively.

The greatest impact, however, is often felt when individuals move between organizations. The skills and behaviors that make someone successful in a large corporation do not automatically translate into success in a start-up environment, and vice versa.

In some future short articles, we will explore these differences in greater detail across specific functions. For professionals considering a move from a corporate environment to a start-up or scale-up, it is important to reflect on which aspects of their experience will remain valuable and which habits or assumptions may need to change. Likewise, start-up and scale-up leadership teams hiring candidates with corporate backgrounds should understand these differences and ask the right questions during the recruitment process to ensure a good fit.

At MD squared B.V. we have a broad experience with supporting both small teams and larger organizations with bringing med tech innovations to market. By bringing experience across different fields, clinical, technical and regulatory and from both corporates and start-ups we work with our clients to explore the different facets that are needed to bring innovations successfully to the market. The multidisciplinary insights allow our clients to make informed choices.

Erik 02

Erik van Dijk

Managing Partner

Don’t hesitate to ask us your questions.

Drop an e-mail or contact us via LinkedIn

This website uses cookies to ensure you get the best experience on our website. If you want to get more information about this, please view our privacy policy page.